Baxter to pay $4bn for dialysis firm


US drug maker Baxter has struck a deal to buy privately-owned Swedish firm Gambro, which makes dialysis products, for $4 billion (£2.5 billion)

‘Baxter has a legacy of innovation in dialysis, including the development of peritoneal dialysis for the treatment of end-stage kidney disease patients in the home,’ said Baxter chief executive Robert Parkinson. ‘This acquisition further strengthens our global dialysis offerings by extending our portfolio in the haemodialysis segment.’

Gambro, which is based in Lund, makes products for haemodialysis and continuous renal replacement therapy, generating annual sales of $1.6 billion in 2011.

According to Baxter, more than two million people are undergoing to some form of ongoing dialysis treatment, with dialysis treatment rates increasing more than 5% annually, in part as a result of rising rates of diabetes and hypertension. The company says that healthcare providers are seeking comprehensive dialysis treatment options that vary by region, in order to serve patients based on clinical need, existing infrastructure and reimbursement policy.


Related Content

Baxter aims to divide and conquer

28 March 2014 Business

news image

Firm will split off its biopharmaceuticals business from medical products

10 years ago - Alain Baxter

1 May 2012 Flashback

news image

British Olympic skier Alain Baxter had his bronze medal taken away after a post-race drug test showed traces of methamphetami...

Most Commented

3D printing cuts fuel cell component costs

4 July 2014 Research

news image

Hardware hackers encouraged to exploit new manufacturing approach in open source schemes

Next Mars rover will make oxygen from CO2

4 August 2014 News and Analysis

news image

Mars 2020 will set Nasa’s space exploration on a self-sufficiency course